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A b s t r a c t
Introduction: Closure of the atrial septal defect in patients with insignificant shunt is controversial. 
Aim: To evaluate the outcomes of transcatheter closure of atrial septal defect (ASD) in symptomatic patients with borderline 
shunt.
Material and methods: One hundred and sixty patients (120 female, 40 male) with a mean age of 30.1 ±16.2 (20–52) years 
with a small ASD who underwent transcatheter closure were analyzed. All patients had a small ASD with Qp : Qs ratio ≤ 1.5, mean 
1.2 ±0.9 (1.1–1.5) in echo examination. Cardiopulmonary exercise tests, clinical study, transthoracic echocardiographic study as well 
as quality of life (QoL) (measured using the SF36 questionnaire (SF36q)) were repeated in all patients before and after the procedure.
Results: The devices were successfully implanted in all patients. After 12 months of ASD closure, all the patients showed a signif-
icant improvement of exercise capacity (oxygen consumption – 21.9 ±3.1 vs. 30.4 ±7.7, p > 0.001). The QoL improved in 7 parameters 
at 12-month follow-up. The mean SF36q scale increased significantly in 141 (88.1%) patients of mean 43.2 ±20.1 (7–69). A significant 
decrease of the right ventricular area (20.3 ±1.3 cm2 vs. 18.3 ±1.2 cm2, p < 0.001) and the right atrial area (15.2 ±1.9 cm2 vs. 12.0 ±1.6 cm2, 
p < 0.001) was observed at 12-month follow-up. 
Conclusions: Closure of ASD in the patients with insignificant shunt resulted in significant durable clinical and hemodynamic 
improvement after percutaneous treatment.
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Introduction
Atrial septal defect (ASD) not uncommonly remains 
undiagnosed until adulthood. The most common present- 
ing symptoms at adult age are palpitations and exercise 
intolerance manifested as either exertional dyspnea or 
fatigue, which increases with age [1–3]. More serious 
complications are typically seen in older patients with 
previously unrecognized ASD who have been exposed to 
large left-to-right shunting for a long period [4, 5].
Patients with a hemodynamically significant ASD could 
be offered surgical or percutaneous closure of the ASD.
Recently, the definition of “significant ASD” has been 
changed. Nowadays significant ASD, according to the ESC 
Guidelines, is defined as shunt with signs of right ventric-
ular volume overload despite the Qp : Qs ratio [1, 4, 5]. 
Patients with significant shunt (signs of right ventricle 
(RV) volume overload) and pulmonary vascular resistance 
< 5 Wood units should undergo ASD closure regardless 
of symptoms [5].
Still the closure of the ASD in patients with insignif-
icant shunt (with Qp : Qs ratio less than 1.5 : 1) and lack 
of pulmonary overload and hypertension is controversial.
Aim
The aim of the present study was to evaluate the 
outcomes of transcatheter closure of secundum ASD in 
patients with a Qp : Qs ratio less than 1.5 : 1.
Material and methods
Patient population
Out of a total of 488 consecutive patients with ASD 
who underwent transcatheter closure over 10 years 
in our department 160 patients (120 female, 40 male), 
mean age of 30.1 ±16.2 (20–52) years, with insignificant 
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shunt were analyzed. The patients had an isolated secun-
dum ASD with a left-to-right shunt (ratio of pulmonary 
to systemic blood flow or Qp : Qs < 1.5 : 1 mean 1.2 ±0.9 
(1.1–1.5) in echo examination). All those patients had co-
existing impairment of physical status or enlargement of 
the right heart cavity or pulmonary hypertension.
The major demographic characteristics of patients 
are summarized in Table I.
Protocol
A detailed description of the transcatheter closure 
technique has been given previously [4, 5]. The procedure 
was performed under local anesthesia. Before the pro-
cedure, a hemodynamic study was performed for all the 
patients. Left-to-right shunt as well as pulmonary artery 
pressure was evaluated by echocardiography and veri-
fied during cardiac catheterization. All procedures were 
performed with continuous transesophageal echocardio-
graphic monitoring. 
After procedure the patients were treated with 75 mg 
acetylsalicylic acid and 75 mg clopidogrel once daily for 
1 month and then 325 mg acetylsalicylic acid for 11 mon- 
ths to provide antithrombotic protection until full device 
endothelialization. 
The assessment was made in compliance with the 
following constraints: 
• clinical study – within 7 days before the procedure and 
then at 1, 6 and 12 months after,
• transthoracic echocardiographic examination – within 
7 days before the procedure and then at 1, 6 and 12 
months after,
• cardiopulmonary exercise test – within 7 days before 
the procedure and then at 6 and 12 months after,
• quality of life measurement – within 7 days before the 
procedure and then at 12 months after.
Clinical study
The clinical study was based on subjective opinion 
of the patients concerning their functional capacity. We 
assessed the frequency of dyspnea incidents and palpi-
tations. 
Transthoracic echocardiographic examination
The transthoracic echocardiographic examination (TTE) 
study was performed using a Toshiba Power Vision ma-
chine with a 5.0-MHz multiplane probe, according to 
a standard protocol including color flow Doppler data. Af-
ter a comprehensive echocardiographic study, right ven-
tricular, right atrial major and minor dimensions, and left 
ventricular dimensions were measured in end-diastole. 
M-mode echocardiography from the parasternal short-ax-
is view was used to measure right ventricular dimensions. 
The apical four-chamber view was used to measure the 
right atrial and ventricle size. The major axis of the right 
atrium was measured from the tricuspid annulus to the 
atrial superior wall and the minor axis was measured per-
pendicular to the major axis at half of the length of the 
latter. Each measurement was averaged from 5 consecu-
tive cardiac cycles. Two independent cardiologists trained 
in echocardiography agreed on the measurements. Fol-
low-up included a complete echocardiographic study with 
a precise location and measurement of any residual shunt 
as well as position of the device.
Cardiopulmonary exercise test
In order to objectively assess the clinical and func-
tional status of the patients in all the cases we performed 
cardiopulmonary exercise tests. 
Maximal cardiopulmonary testing was performed on 
an ergometer cycle. Peak oxygen uptake, carbon diox-
ide production, and minute ventilation were measured 
with a computerized breath-by-breath analyzer (V-MAX 
29, Sensor-Medics). Patients performed a maximal exer-
cise test using a 1-min incremental bicycle protocol with 
a work rate increment of 10 W/min. Criteria for test ending 
were considered patient exhaustion or a respiratory ex-
change ratio ≥ 1.09. A 12-lead electrocardiogram was also 
monitored throughout the study, and cuff blood pressure 
was determined manually every 2 min. Standard equa-
tions were used to generate predicted values for baseline 
spirometric and peak exercise parameters.
Quality of life
This objective study was completed with the sub-
jective opinions of the patients concerning their clini-
cal status. In each case we assessed the quality of life 
using the SF36 questionnaire. The patients completed 
the questionnaire SF36 – the best-known questionnaire 
in measuring health status. The number “36” refers to 
36 questions which concern 8 aspects of general health 
and quality of life – that is: physical function, role-phys-
ical, bodily pain, general health, vitality, social function, 
role-emotional and mental health. 
Table I. Demographic characteristics of patients 
(n = 160)
Parameter Results
n (%)
Smoking 20 (12.5)
Obesity 16 (10)
Diabetes mellitus 4 (2.5)
Hypertension 45 (28.1)
Dyslipidemia 51 (31.9)
Coronary artery disease 1 (0.6)
Atrial fibrillation 17 (10.6)
Pulmonary hypertension* 16 (10)
Measured in right-heart catheterization: pulmonary hypertension – mean pul-
monary artery pressure ≥ 25 mm Hg
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Statistical analysis
Continuous data are expressed as mean ± standard 
deviation and baseline and follow-up were compared by 
the paired Student’s t-test. For the comparison of cate-
gorical variables the χ2 test was used. The level of statis-
tical significance was two-sided and set at p < 0.05. Sta-
tistical analysis was performed with SPSS version 15.0.0 
for Windows.
Results
The left-to-right shunt (Qp : Qs) in hemodynamic 
evaluation before ASD closure was comparable to mea-
surement of Qp : Qs in the echo examination (1.3 ±0.6 
(1.1–1.6) vs. 1.2 ±0.9 (1.1–1.5), p = 0.598). Pulmonary hy-
pertension measured in right-heart catheterization was 
found in 16 (10%) patients (mean PAP 16 ±3.5 (11–24), 
systolic PAP 29 ±7.5 (19–35)).
The defect echo diameter was 7.0 ±3.4 (4–15) mm. 
The mean balloon stretched diameter of ASD was 9.6 
±6.1 mm (6–18 mm). 
The devices were successfully implanted in all the 
subjects (procedure time 18.8 ±4.8 (9–35) min, fluorosco-
py time 8.5 ±4.9 (6–13) min). The diameter of the implant-
ed devices ranged from 8 mm to 20 mm. The Amplatzer 
ASD closure device was used in 105 (65.6%) patients, the 
Starflex device in 10 (6.3%) patients, and Cardia ASD de-
vice in 45 (28.1%) patients.
Minor complications were recorded in 15 (9.4%) pa-
tients with minor venous access bleeding without trans-
fusion. In 25 (15.6%) cases transient rhythm disorders 
were noted. There were no serious complications in-
volved, no fractures of the device, and no device embo-
lizations.
All the patients remained well with no complications 
or new symptoms at their 12-month follow-up. No pa-
tient has had any heart-related hospital admissions. All 
the patients had complete 12-months follow-up.
Clinical study
Transcatheter closure of secundum ASD has created 
significant improvement of the clinical status of the pa-
tients in the early follow-up. It caused reduction of the 
breathlessness and palpitation as early as a month after 
the procedure (Figures 1 and 2).
Transthoracic echocardiographic examination
Directly after the procedure transthoracic echocardi-
ography showed residual trivial shunt in 13 (9.3%) sub-
jects, which disappeared in all cases within the 6-month 
follow-up period. 
As early as 1 month after the procedure, a significant 
decrease of the right ventricular dimension and the right 
atrial dimension was observed. All the analyzed dimen-
sions of the right heart significantly decreased (Table II). 
Cardiopulmonary exercise tests
Significant improvement of exercise capacity was 
noted at 6 and 12 months after the procedure. The time 
of exercise within 6 months of ASD closure was longer, 
as compared to the baseline values and also the oxygen 
consumption increased (Table III).
Quality of life
Apart from the objective improvement of physical ac-
tivity in the cardiopulmonary exercise test, significant im-
provement of the quality of life in patients based on the 
SF36 form was also noted. Moreover, an improvement of 
each aspect of quality of life with the exception of mental 
health was observed. The mean SF36q scale increased 
significantly in 141 (88.1%) patients of mean 43.2 ±20.1 
(7–69). The total SF36 scale improved from 34.2 to 70.2 
points (Table IV). 
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Figure 1. Frequency of dyspnea before and after 
ASD closure
Figure 2. Frequency of palpitations before and 
after ASD closure
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The canonical correlation analysis showed that the 
following parameters had an influence on improvement 
of the total SF36 scale: improvement in cardiopulmonary 
test (prolonged time of exercise, improvement of VO
2peak
 
(ml/kg/min)), p < 0.05. The right-to-left shunt (Qp : Qs) 
before ASD closure had no influence on improvement of 
the total SF36 scale (p < 0.621).
The multiple forward stepwise regression analysis re-
vealed that of all parameters (parameters of echocardiog-
raphy study and cardiopulmonary exercise test) reduction 
in right heart size after ASD closure (δRV
area
 (cm2); F(6.31) = 
9.0141; p < 0.001, standard error 2.210) had the strongest 
influence on improvement of the total SF36 scale.
Discussion
Isolated ASD constitutes the second most common 
(after bicuspid aortic valve) congenital heart lesion in 
adults [1, 2].
Table II. Echocardiographic parameters before and after ASD closure
Parameter Before ASD 
closure
1 month after 
ASD closure
6 months 
after ASD 
closure
12 months 
after ASD 
closure
Value of
p before
vs. 1 month
Value of
p
before
vs. 6 months
Value of
p
before
vs. 12 
months after
RV
diastole
 [mm] 31.4 26.9 26.6 25.2 < 0.001 < 0.001 < 0.001
RV
systole
 [mm] 26.9 22.1 21.2 21.1 < 0.001 < 0.001 < 0.001
RV
long axis
 [mm] 67.2 64.9 64.9 65.0 < 0.001 < 0.001 < 0.001
RV
short axis
 [mm] 41.6 33.9 31 30.8 < 0.001 < 0.001 < 0.001
RV
area
 [cm2] 20.3 21 19.9 18.3 < 0.001 < 0.001 < 0.001
RA 
ong axis
 [mm] 48.1 42.2 39.0 39.1 < 0.001 < 0.001 < 0.001
RA
short axis
  [mm] 40.1 34.1 33.0 33.0 < 0.001 < 0.001 < 0.001
RA
area
 [cm2] 15.2 14 12.9 12.0 < 0.001 < 0.001 < 0.001
Table III. Parameters of the cardiopulmonary exercise test before and after ASD closure
Parameter Before ASD closure 6 months after ASD 
closure
12 months after ASD 
closure
Value of p before vs. 
12 months after
Time of exercise [s] 689 ±108 789 ±113 903 ±175 < 0.001
Heart rate [beats/min] 155 ±30 164 ±29.8 172 ±29 < 0.01
Heart rate %  81 ±10.9 91 ±13 91.1 ±12.9 < 0.001
VO
2peak
 [ml/kg/min] 21.9 ±3.1 30.1 ±8 30.4 ±7.7 < 0.001
VO
2peak
 % 71 ±12.2 83 ±17 86.3 ±16 < 0.001
VCO
2
 [l/min] 1.55 ±0.9 1.56 ±1.1 1.83 ±0.8 < 0.001
Pulse O
2
11.1 ±2.0 13.2 ±2.2 13.5 ±2.1 < 0.001
VD/VT 0.22 ±0.1 0.16 ±0.05 0.16 ±0.06 < 0.01
VE/VCO
2
31.6 ±3.2 27 ±4.6 26.5 ±4.2 < 0.05
PETO
2
 [kPa] 14.1 ±0.9 14 ±0.2 14.2 ±0.8 NS
PETCO
2
 [kPa] 4.9 ±0.6 5.0 ±0.4 5.0 ±0.1 NS
T
AT
 [s] – time to attain anaerobic 
treasure 
413 ±101 524 ±139 532 ±125 < 0.001
VO
2AT
 [ml/kg/min] 16.0 ±12.02 17.1 ±14.8 19.8 ±14.7 < 0.001
VO
2AT
 % 44 ±11.9 45.2 ±11.0 50 ±11.6 < 0.001
VO
2peak
 – peak oxygen consumption, VCO
2
 – production of carbon dioxide, pulse O
2
 – oxygen pulse, VD/VT – tidal volume, VE/VCO
2
 – ventilatory equivalent for CO
2
, 
TAT – time to attain anaerobic treasure, VO
2AT
 – oxygen consumption at anaerobic threshold
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Surgical closure of ASD has been practiced for about 
45 years [3, 4]. Since the first attempt in 1976, transcath-
eter closure of secundum ASD has evolved over the past 
three decades [5–8]. and now according to guidelines is 
the therapy of choice when possible [8].
The benefits of transcatheter treatment of congeni-
tal heart diseases are obvious. First of all, we can avoid 
complications of open heart surgery, which is absolutely 
crucial in the group of patient with insignificant shunt. 
Another benefit is avoidance of a surgical scar commonly 
called by psychologists a “scar of the human soul” and 
shorter hospitalization time [8, 9]. It allows even percuta-
neously, the closure of the ASD in the patients with insig-
nificant shunt is controversial. Some authors undermine 
the necessity to correct atrial communications in those 
cases, giving the argument that the risk involved in the 
procedure is greater than its benefit.
However, based on some analyses, it would appear 
that ASD should be closed when they are identified, irre-
spective of the patient’s symptoms [10–14].
“Significant ASD” (defined as shunt with pulmonary 
to systemic blood flow Qp : Qs over 1.5 : 1) has been an 
indication for intervention in ASD for the last several 
years. Nowadays significant ASD, according to the ESC 
Guidelines, is defined as shunt with signs of right ven-
tricular volume overload despite Qp : Qs [8, 15]. Also 
patients who are asymptomatic or mildly symptomatic 
should be offered defect closure, because the natural 
course of untreated ASD often leads to a shortened life 
expectancy compared with healthy subjects [16, 17]. Bro-
chu et al. showed that even adult ASD patients classified 
as asymptomatic showed a significant increase in their 
functional capacity after percutaneous closure [18].
The aim of our study was to evaluate the results of 
transcatheter closure of ASD in patients with insignifi-
cant shunt defined as shunt with Qp : Qs < 1.5 : 1. All 
those patients had coexisting subjective impairment of 
physical status or enlargement of the right heart cavity 
or pulmonary hypertension. 
In our conviction patients with a small ASD without 
clinical symptoms and with normal right heart and nor-
mal pulmonary artery pressure may remain under med-
ical observation as there is no reason to close the ASD. 
Conversely, patients with clinical impairment and/or 
right heart enlargement could benefit from ASD closure. 
In our patients we found a significant reduction in 
right heart dimension after device closure. Nearly all pa-
tients showed reduction of symptoms and an improve-
ment in functional and exertional capacity in cardiopul-
monary exercise tests. The quality of life measured by the 
SF36 test improved. Improvement in exercise capacity 
had the greatest influence on the improvement of quality 
of life in our patients. Moreover, improvement in exercise 
capacity was correlated with better quality of life after 
ASD closure. On the other hand, the left-to-right shunt 
before ASD closure had no influence on improvement of 
the quality of life. Even the patients with the minimal 
shunt benefit from ASD closure, in terms of quality of life 
and exercise capacity. 
Our analysis revealed that of all analyzed parameters 
only reduction in right heart size after ASD closure had 
a significant influence on improvement of the total SF36 
scale as well as exercise capacity. This therefore suggests 
that in patients with insignificant shunt, enlargement of 
the right ventricle should be one of the main criteria for 
ASD closure.
Our study results confirm that device closure of ASD 
is safe with minimal complications, which is consistent 
with the reports in the literature [18–22].
Thus we are convinced that it is really worth closing 
ASD despite the Qp : Qs ratio in patients with coexist-
ing impairment of physical status or enlargement of the 
right heart cavity. 
Of course, each case should be analyzed and quali-
fied individually, and other reasons for physical impair-
ment should be excluded, especially in older patients.  
Conclusions
Transcatheter closure of ASD in symptomatic patients 
with borderline shunt is associated with marked clinical, 
functional and quality of life improvement.
Table IV. Results of the SF 36 questionnaire before and after ASD closure
Parameter Before ASD closure 12 months after Value of p
SF36 Total scale 34.2 ±4.9 70.2 ±8.9 < 0.001
PF – Physical function 8.2 ±1.1 10.2 ±4.2 < 0.01
RP – Role physical 6.1 ±2.7 10.1 ±1.1 < 0.01
BP – Bodily pain 7.0 ±4.0 14.2 ±4.0 < 0.01
GH – General health 4.2 ±4.9 11.9 ±4.0 < 0.001
V – Vitality 7.2 ±3.3 11.2 ±3.3 < 0.01
SF – Social function 9.2 ±3.9 14.2 ±4.5 < 0.01
RE – Role emotional 14.1 ±7.3 19.1 ±8.9 < 0.01
MH – Mental health 4.2 ±4.9 4.7 ±4.0 0.78
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